【摘要】 目的探讨乳腺癌特异基因(BCSG1)在乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S-P法和荧光定量PCR方法检测36例乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果36例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小(P<0.01),病灶缓解率(CR+PR)为85.6%;新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前(P<0.05),BCSG1蛋白高表达率低于新辅助化疗前(P<0.01)。结论乳腺癌新辅助化疗后BCSG1在分子和蛋白水平表达均明显降低,与新辅助化疗后疗效呈负相关(r=-0.539,P<0.01),提示BCSG1可作为乳腺癌新辅助化疗疗效的预测因子。更多还原

【Abstract】 Objective To study the value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy(NC) for breast cancer.Methods The expression of BCSG1 in cancer tissue was assayed by immunohistochemistry and RT-PCR in 36 cases of breast cancer patients before and after receiving NC of CEF(cyclophosphamide,epirubicin and fluorouracil) regimen.The therapeutic response of NC was evaluated by morphological and pathological observation.The relationship between expression of BCSG1 and morphological response to NC was analyzed.Results Among the studied cases,the diameter of tumor significantly decreased(P<0.01)and the improvment rate of the treatment effect(CR+PR) was 85.6%.The expression of BCSG1 mRNA(P<0.05)and the high expression rate of BCSG1(P<0.01)were decreased significantly after receiving NC than that before NC.Conclusions After NC,the expression of BCSG1 mRNA and protein was decreased significantly,which had negative relation to the therapeutic effect of NC.BCSG1 can be a prognosticate gene to evaluate the effect of NC in breast cancer patients.更多还原